Factors affecting integration of an early warning system for antimalarial drug resistance within a routine surveillance system in a pre-elimination setting in Sub-Saharan Africa
To address the current threat of antimalarial resistance, countries need innovative solutions for timely and informed decision-making. Integrating molecular surveillance for drug-resistant malaria into routine malaria surveillance in pre-elimination contexts offers a potential early warning mechanism for further investigation and response. However, there is limited evidence on what influences the performance of such a system in resource-limited settings. From March 2018 to February 2020, a sequential mixed-methods study was conducted in primary healthcare facilities in a South African pre-elimination setting to explore factors influencing the flow, quality and linkage of malaria case notification and molecular resistance marker data. Using a process-oriented framework, we undertook monthly and quarterly data linkage and consistency analyses at different levels of the health system, as well as a survey, focus group discussions and interviews to identify potential barriers to, and enhancers of, the roll-out and uptake of this integrated information system. Over two years, 4,787 confirmed malaria cases were notified from 42 primary healthcare facilities in the Nkomazi sub-district, Mpumalanga, South Africa. Of the notified cases, 78.5% (n = 3,758) were investigated, and 55.1% (n = 2,636) were successfully linked to their Plasmodium falciparum molecular resistance marker profiles. Five tangible processes-malaria case detection and notification, sample collection, case investigation, analysis and reporting-were identified within the process-oriented logic model. Workload, training, ease of use, supervision, leadership, and resources were recognized as cross-cutting influencers affecting the program's performance. Approaching malaria elimination, linking molecular markers of antimalarial resistance to routine malaria surveillance is feasible. However, cross-cutting barriers inherent in the healthcare system can influence its success in a resource-limited setting.
Authors
- Philippe J. Guérin (ORCID: https://orcid.org/0000-0002-6008-2963)
- Elizabeth Allen (ORCID: https://orcid.org/0000-0003-3064-5267)
- Richard J. Maude (ORCID: https://orcid.org/0000-0002-5355-0562)
- Aaron Mabuza
- Karen I. Barnes (ORCID: https://orcid.org/0000-0002-5547-820X)
- Jaishree Raman (ORCID: https://orcid.org/0000-0003-0728-3093)
- Ray Magagula
- Gillian Malatje
- Frank Kagoro (ORCID: https://orcid.org/0000-0003-4608-7167)
- Mehul Dhorda (ORCID: https://orcid.org/0000-0002-7849-3293)
- Gerdalize Kok
Institutions
- WWF Colombia (CO)
- University of Cape Town (ZA)
- University of the Witwatersrand (ZA)
- The Open University (GB)
- Mahidol University (TH)
- University of Mpumalanga (ZA)
- University of Oxford (GB)
- National Center for Emerging and Zoonotic Infectious Diseases (US)
- Mahidol Oxford Tropical Medicine Research Unit (TH)
- Infectious Diseases Data Observatory (GB)
- University of Pretoria (ZA)
- University of Hong Kong (HK)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-06-03
- DOI
- https://doi.org/10.1371/journal.pone.0305885
- Primary Topic
- Pharmaceutical Quality and Counterfeiting
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bill and Melinda Gates Foundation
- Wellcome Trust
- South African Medical Research Council
- ExxonMobil Foundation
- Medical Research Council